Somatropin - Grandis Biotech
Alternative Names: GrandiTropin T; InfiTropin CRLatest Information Update: 24 Oct 2021
At a glance
- Originator CSL
- Developer Grandis Biotech; InfiMed Therapeutics; Kowa Pharmaceutical
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Growth disorders; Somatotropin deficiency; Turner's syndrome
Most Recent Events
- 16 Jul 2007 Discontinued - Phase-III for Growth disorders in European Union (Parenteral)
- 16 Jul 2007 Discontinued - Preclinical for Somatotropin deficiency in Japan (Parenteral)
- 16 Jul 2007 Discontinued - Preclinical for Somatotropin deficiency in USA (Parenteral)